Key Drivers
- Strong Margins
- High Leverage
- Lower Valuation
AIAI Summary
Zoetis is a high-quality but now turnaround-dependent investment: its depressed valuation and oversold shares offer upside only if U.S. companion-animal prescriptions and pricing stabilize, while continued rebates, competition, or another guidance cut could validate a more permanent erosion of its premium growth and margin profile.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Margins
- •High Leverage
- •Lower Valuation
ZTS delivers strong profitability and cash generation, but elevated leverage and declining cash warrant caution despite a more attractive valuation.
Price Behavior
Key Price Behavior Insights:
- •Falling short-term trend
- •Oversold momentum
- •Support under pressure
ZTS remains bearish after falling 4.8% last month, with $71.40 support and an oversold RSI suggesting a rebound only if it reclaims $73.00–$73.60.
Deeply oversold
Sentiment & News
Key News Insights:
- •U.S. demand softness
- •Margin pressure
- •International resilience
Zoetis faces near-term U.S. pet-care weakness and margin pressure, but international growth, buybacks, and pipeline potential support a longer-term recovery case.
Near-term sentiment may remain pressured until U.S. companion-animal demand and profitability stabilize
Similar Companies in Healthcare
Other companies in the same sector with AI ratings